Expertise in
6
conditions

Joe J. Sasadeusz

Elizabeth Street, 
Melbourne, VIC, AU 
Expertise in
6
conditions
Elizabeth Street, 
Melbourne, VIC, AU 

Overview

Joe Sasadeusz practices practicing medicine in Melbourne, Australia.

Sasadeusz is highly rated in 6 conditions, according to our data. Their clinical expertise encompasses Hepatitis, Hepatitis B, Hepatitis C, HIV/AIDS, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 71 peer reviewed articles and participating in 5 clinical trials.

Locations

Elizabeth Street, Melbourne, VIC 3000, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Five Year Plan of Enhanced HCV Monitoring, Primary Care-Based Workforce Development, Rapid Scale-up of HCV Treatment and Public Health Policy Action in HIV Positive Individuals Within Australia.
A Five Year Plan of Enhanced HCV Monitoring, Primary Care-Based Workforce Development, Rapid Scale-up of HCV Treatment and Public Health Policy Action in HIV Positive Individuals Within Australia.
Enrollment Status: Unknown
Publish Date: September 08, 2021
A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia
A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

71 Total Publications

Consensus guidelines for the subsequent management of neutropenic fever after empiric therapy.
Consensus guidelines for the subsequent management of neutropenic fever after empiric therapy.
Journal: Internal medicine journal
Published: October 16, 2025

Frequently Asked Questions about Joe J. Sasadeusz

Is Joe J. Sasadeusz a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Joe J. Sasadeusz is classified as an Distinguished expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Joe J. Sasadeusz participate in research or clinical trials?

Yes. Joe J. Sasadeusz has published 71 articles and abstracts on conditions like Hepatitis. You can view a list of Joe J. Sasadeusz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sasadeusz's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile